OneMedNet Corporation has signed its 12th channel partner agreement with a leading global pharmaceutical intelligence provider to distribute its U.S.-sourced, de-identified clinical Real-World Data (RWD) worldwide. This partnership enhances OneMedNet's presence in the fast-growing pharmaceutical data market, projected to grow from $2.7 billion in 2026 to $7.1 billion by 2033. OneMedNet's direct-from-source, regulatory-grade data is valued for its quality and compliance, supporting drug development, regulatory submissions, and AI applications. The company continues to expand its commercial reach while maintaining control over data sourcing and curation.
OneMedNet's expansion in pharmaceutical intelligence coincides with a mixed Health-sector market on Pluang, where 68 of 150 US stocks rose and 54 fell as of Oct 19, 2026 18:43 WIB. For readers following Health-sector stocks, Arrowhead Pharmaceuticals Inc. (ARWR) traded at USD 56.94 with a 1-day change of +1.86% and a typical hold time of 10 days, Twist Bioscience Corp (TWST) at USD 135.06 with +1.74% and 27 days hold time, and Hims and Hers Health Inc (HIMS) at USD 28.48 with +1.46% and 22 days hold time.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
